Business & Operations Announcements

Guangzhou Yipin Hong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Yipin Hong Pharmaceutical Group Co., Ltd., has obtained a registration certificate for Procaterol Hydrochloride Oral Solution from the NMPA. This expands the company's product pipeline and enhances its competitiveness in the pediatric drug market. The company faces market and environmental risks impacting sales.

Zhuhai Rundu Pharmaceutical Co., Ltd. announced it has received a drug registration certificate from the NMPA for its Isosorbide Dinitrate Injection. This product is indicated for unstable angina and vasospastic angina. The approval enhances the company's cardiovascular product portfolio and promotes an integrated industrial chain from raw materials to finished products.

Beiken Energy Holdings Group Co., Ltd. announces the decision to deregister its wholly-owned subsidiary, Beiken Energy Kish Co. Ltd. This move aims to optimize resource allocation and reduce operating costs. The company expects this action to positively impact its overall profitability and does not foresee any adverse effects on its operations or shareholder interests.

Qinglong Pipeline Co., Ltd. announced the signing of a sales contract for cement products with the Ningxia Hui Autonomous Region Water Conservancy Engineering Construction Center. The contract value is RMB 224.51 million, representing 8.54% of the company's 2025 audited revenue. The contract is expected to impact the company's performance in 2026-2027.

Guangdong Zhongsheng Pharmaceutical Co., Ltd. announced that its subsidiary, Zhongsheng Ruichuang Biotechnology Co., Ltd., has obtained a patent certificate from the Japan Patent Office for the crystal form and preparation method of a ketone amide derivative. This patent is a core patent for the company's oral drug Leritrelvir (乐睿灵®), an anti-novel coronavirus drug. The patent is expected to enhance intellectual property protection and leverage the company's independent intellectual property advantages.

Shanghai Hongying Intelligent Technology Co., Ltd. announced a major EPC contract for its wholly-owned subsidiary, Hongying New Energy, to construct a 200MW/800MWh independent energy storage power station in Gansu. The contract value is RMB 664 million, with Hongying New Energy responsible for RMB 532 million. This project is expected to positively impact the company's future performance and strengthen its position in the new energy storage sector.

Changchun High-Tech Industries (Group) Inc. announces its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received a Drug Registration Certificate from China's National Medical Products Administration for its injectable leuprolide acetate (II). This approval is for the treatment of central precocious puberty (CPP) in children weighing over 20kg. The product is expected to enhance the company's market competitiveness in pediatric health.

This announcement details that the company's wholly-owned subsidiary, Jiangxi Yaodu Zhangshu Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for Qingfei Tang Granules. This approval allows the product to be marketed, enriching the company's product line and enhancing market competitiveness. The company has invested approximately RMB 8 million in R&D for this product.

Tianma Microelectronics' subsidiaries will sign contract energy management agreements with related party China Aviation International Supply Chain for distributed photovoltaic power stations. The agreements aim to reduce carbon emissions and operating costs. The total transaction value over 25 years is estimated at RMB 671.73 million. The transaction is considered a related party transaction and has been approved by the board.

Zhejiang Weikang Pharmaceutical Co., Ltd. announced its product, Ganmao Qingre Granules, was selected in the National Chinese Patent Medicine Group Centralized Procurement. This selection is expected to expand sales and market share, positively impacting future performance. However, the final contract signing and sales are subject to market and policy uncertainties.

Shandong Jincheng Pharmaceutical Group Co., Ltd. announces the progress of transferring drug production technology and MA holder rights. The subsidiary has received full payment and completed the MA holder change. This transfer is expected to impact net profit by approximately 47.17 million RMB, exceeding 10% of the previous year's audited net profit. Investors are advised to be aware of investment risks.

Beijing Jiuhui Biotechnology Co., Ltd. announced it has received an invention patent certificate from the China National Intellectual Property Administration. The patent is for the use of a mutant 6-phosphogluconate dehydrogenase in preparing detection reagents. This patent is expected to enhance the company's core competitiveness and foster continuous innovation.

Xiamen Ad Biomedicine announced it has obtained one invention patent certificate from the China National Intellectual Property Administration. The patent is for a method for detecting copy number variations in single samples using next-generation sequencing. While not significantly impacting near-term operations, the patent enhances the company's intellectual property protection and supports innovation.

This announcement details the progress of the deregistration of two wholly-owned subsidiaries, Ningbo JZHF Network Technology Co., Ltd. and Jinhua JZHF Network Technology Co., Ltd. The company has received confirmation of the deregistration completion from the relevant market supervision administrations. This action will not adversely affect the company's financial performance or shareholder interests, as the subsidiaries will no longer be included in the consolidated financial statements.

Qinglong Pipe Industry Group Co., Ltd. has been confirmed as the winning bidder for the PCCP pipe material procurement project for the Guangxi Northwest Drought Relief Longjiang River Valley Irrigation District. The contract value is RMB 556.54 million, representing 21.18% of the company's 2025 audited operating income. This award is expected to impact the company's performance from 2026 to 2030.

Guizhou Bailing announced that its products, including Yindan Xinnuotong Soft Capsules, Hufu Tablets, and Qiangli Pipaye Dew, were selected in the national centralized procurement of Chinese patent medicines. This is expected to expand sales, increase market share, and positively impact future operating performance. The company is awaiting contract signing, and sales are subject to policy and market uncertainties.

China National Engineering International Co., Ltd. announced its subsidiary signed an EPC contract for a 100MW/102MWh independent hybrid energy storage power station in Hefei, Anhui Province. The contract value is RMB 1.12738 billion, representing 9.75% of the company's projected 2025 revenue. This contract is expected to expand the company's new energy business.

Yifan Pharmaceutical's wholly-owned subsidiary, Suzhou Yifan Pharmaceutical, has won the bid for its Strong Cough Syrup in the National Chinese Patent Medicine Procurement Alliance's centralized procurement. The product is a national medical insurance catalog item. While current sales contribution is small, the win is expected to increase product accessibility and brand influence, though contract signing and market execution remain uncertain.

Jilin Chemical Fiber Co., Ltd. received a government subsidy of RMB 9.55 million from the Jilin Provincial Department of Finance. This subsidy is related to the company's daily operations and represents 42.01% of its net profit attributable to shareholders. The company will recognize this as other income, impacting its 2026 profit before tax.

SF Holding reports May 2026 business performance. Total revenue grew 5.87% year-over-year to RMB 265.86 billion. Express logistics revenue increased slightly by 0.36%, while supply chain and international business revenue surged 24.49%, driven by strategic initiatives and market opportunities.

Kangmei Pharmaceutical Co., Ltd. announced that its product, Ganmao Qingre Granules, has successfully won the bid in the National Traditional Chinese Medicine Procurement Alliance's centralized volume-based procurement. The procurement cycle runs from the actual implementation date through December 31, 2028. This outcome is expected to enhance the product's market share and strengthen the company's competitiveness in the cold medication sector. The company will now proceed with signing formal procurement contracts.

This announcement details that Yangpu Medical's wholly-owned subsidiary received medical device change registration and renewal registration documents from regulatory authorities. These approvals ensure product compliance and sustainability, enhancing the company's competitiveness. While positive for future development, actual sales may be affected by market conditions, introducing uncertainty to future performance.

Ningbo Tianyi Medical Appliances Co., Ltd. has received a Medical Device Registration Certificate from the National Medical Products Administration for its disposable continuous renal replacement therapy (CRRT) tubing. This product is compatible with Fresenius multiFiltratePRO equipment, enhancing the company's product portfolio in the critical care sector. The company expects this to strengthen its market position in blood purification, though actual sales performance remains subject to future market promotion efforts.

Shenzhen Jameetech Co., Ltd. announces the completion of the deregistration of its joint venture subsidiary, Jiangxi Jiean Mining Technology Co., Ltd. This action is aimed at reducing management costs and optimizing resource allocation. The deregistration will not affect the company's overall business development or profitability and does not harm shareholder interests.

Hubei Hekon Gas Co., Ltd. announces that its subsidiary, Hubei Hekon New Materials Co., Ltd., has obtained an invention patent for a trichlorosilane synthesis tail gas pressure swing adsorption recovery system and method. This patent is expected to enhance the company's technological capabilities in tail gas recovery and utilization.

Guizhou Chuanheng Chemical Co., Ltd. announced it has received one patent certificate from the China National Intellectual Property Administration. The patent relates to a crystal habit modifier and its application in phosphogypsum from wet-process phosphoric acid production. This technology is already in use by the company and is expected to improve phosphogypsum utilization and strengthen the company's intellectual property system.

STO Express announces its May 2026 operational data. Revenue increased by 30.23% year-on-year to RMB 5.744 billion. Parcel volume grew 18.78% to 2.689 billion, and average revenue per parcel rose 9.74% to RMB 2.14. These figures reflect the consolidation of Zhejiang Daniao Logistics.

Shandong Yabo Technology Co., Ltd. announces progress on its wholly-owned subsidiary, Zhongfu Kai New Energy Technology, signing an EPC general contracting contract for the Tengzhou Xigang Town 200MW/400MWh Energy Storage Power Station Project. The contract value is approximately RMB 194 million, representing 66.19% of the company's 2025 audited revenue. The project is expected to positively impact future operating performance.

Beijing Zhongke Sanhuan High-Tech Co., Ltd. announces its subsidiary, Ningbo Sanhuan Magnetic Sound Industry and Trade Co., Ltd., and its subsidiary Ningbo Zhongci Trading Co., Ltd. have received government subsidies totaling RMB 18.01 million. These subsidies are related to revenue and have been received in cash. The company expects these subsidies to increase its total profit by RMB 18.01 million in 2026.

Oriental Fortune's wholly-owned subsidiary, Shanghai Tiantian Fund Sales Co., Ltd., has entered into a cooperation agreement with China Minsheng Bank Shanghai Branch for comprehensive credit. Oriental Fortune will provide an irrevocable joint liability guarantee for this credit line, with a maximum guarantee amount of RMB 4 billion. This matter is within the scope of authorization from the 2025 annual shareholder meeting.

Su's Ke Group Co., Ltd. announced receiving government subsidies of RMB 19 million, accounting for 80.80% of its net profit. The subsidies are related to revenue and are expected to increase the company's total profit by RMB 19 million in 2026. The final accounting treatment and impact will be subject to the annual audit.

Jiangsu Kailun Building Materials Co., Ltd. received government subsidies totaling 19.7388 million RMB, related to revenue and daily operations. This amount represents 96.77% of the company's net profit attributable to shareholders. The subsidies are expected to increase the company's total profit in 2026.

Qingdao Neusoft Carrier Co., Ltd. announces that its wholly-owned subsidiary, Shanghai Neusoft Carrier Microelectronics Co., Ltd., has obtained an invention patent certificate from the National Intellectual Property Administration. The patent is for a data storage method and device for Flash simulating EEPROM in embedded systems. This is expected to enhance the company's core competitiveness.

Xingyun Technology's wholly-owned subsidiary, Shenzhen Xingyun, signed a 5-year computing power service agreement with a VB customer for RMB 1.01376 billion. The contract is expected to impact the company's operating results and supports its transformation strategy. The company has assessed associated risks, including performance and macroeconomic factors.

Sailun Pharma's wholly-owned subsidiary has obtained a drug registration certificate for Aspartate Potassium Magnesium Injection from the NMPA. This product is mainly used for treating hypokalemia and as an auxiliary treatment for ventricular arrhythmias caused by digitalis poisoning, sequelae of myocarditis, congestive heart failure, and myocardial infarction. The approval enriches the company's product portfolio.

Guangdong High Leap Co., Ltd. signed a 5-year, RMB 3.557 billion service procurement agreement for computing power. The contract is expected to increase revenue but may have limited profit impact in 2026, with potential risks in customer demand, performance, and execution. The company has arranged resources to mitigate these risks.

Sichuan Transportation Machinery Group announced the signing of a sales and installation contract for the first phase of the open-pit mining conveyor system for the Hongge South Vanadium Titanium Magnetite Mine project. The contract value is RMB 307,742,602.00. This contract is within the company's main business and is expected to positively impact future financial performance.

Changshu Tianyin Electromechanical Co., Ltd. announced it has obtained an invention patent certificate from the National Intellectual Property Administration for a commercial refrigeration compressor motor starter structure. This patent is related to the company's existing products and aims to improve modularity and installation efficiency. The acquisition is expected to enhance the company's intellectual property protection and core competitiveness.

Guizhou Chuanheng Chemical Co., Ltd. has received a patent certificate for a method of preparing dihydrate gypsum from hemihydrate phosphogypsum. This invention is expected to promote the green utilization of phosphogypsum byproducts, improve resource utilization, and enhance the company's innovation mechanism and core competitiveness. The patent is not expected to have a significant impact on the company's current operating conditions.

Chow Tai Fook Jewelry Co., Ltd. announces the opening of six new self-operated stores in May 2026, as per SZSE regulations. These stores are located across various regions including East China, Southwest China, and South China. The report details store names, locations, opening dates, operating areas, investment amounts, and main product categories.

Sunflower Pharmaceutical Group's subsidiary has obtained a drug registration certificate for Flurbiprofen Gel Patch from the NMPA. This non-steroidal anti-inflammatory drug (NSAID) offers topical pain relief with reduced gastrointestinal side effects. The approval allows the company to enter the pain management market, aiming to develop this category into a new growth driver for the "elderly" segment.

Tianjin Life Science & Technology Co., Ltd. announces that its Glipizide Controlled-Release Tablets (5mg) have received approval for market launch from the National Medical Products Administration. This approval expands the company's endocrine product line and enhances market competitiveness. The drug is classified as a Category 4 chemical drug, considered equivalent to a first-time approval.

Juyuan Co., Ltd. announced it has obtained three new patent certificates from the PRC Intellectual Property Office, including one invention patent, one utility model patent, and one design patent. These patents are widely used in the company's main business areas and will strengthen its intellectual property protection and competitive advantage.

Xinjiang Beixin Road & Bridge Group Co., Ltd. announced it has been awarded a contract for asphalt pavement construction on the Yu'an Expressway, Section 2, in Chongqing. The contract value is RMB 205.59 million, representing 1.82% of the company's 2025 audited revenue. This award is expected to enhance market competitiveness and share.

Sichuan Haowu Electromechanical Co., Ltd. announces that its wholly-owned subsidiary, Neijiang Pengxiang, has signed a termination agreement with Dongfeng Nissan Auto Finance Co., Ltd. to end a guarantee contract. The termination is due to the subsidiary Tianjin Junhao having exited its business and fully repaid its auto loan. This action has no adverse impact on the company or its shareholders.

Renhe Pharmaceutical's subsidiary, Jiangxi Yaodu Renhe Pharmaceutical, has received a Drug Registration Certificate from the National Medical Products Administration for Oseltamivir Phosphate Dry Suspension. This approval allows the company to produce and market the drug domestically, enhancing its competitiveness in the anti-infective sector. The company has invested approximately RMB 11 million in R&D for this project.

Guanglian Aviation announced it signed a major sales contract worth RMB 58.192 million for UAV composite material wing components. The contract, with a unit under AVIC, is expected to positively impact the company's performance. It does not affect business independence or create customer dependency.

AnkeRui Electric Co., Ltd. announced it has obtained 9 invention patent certificates from the State Intellectual Property Office. These patents cover various areas including reactive power compensation control, network interface protection, and communication systems. The company expects these patents to strengthen its market position and enhance its core competitiveness.

China Energy Conservation Guozhen Environmental Protection Technology Co., Ltd. announces the early termination of the PPP project contract for the Wuqiao County Urban Sewage Treatment Plant. The termination is due to government reforms and aims to optimize resource allocation. The company will receive compensation and outstanding service fees through legal proceedings, with the final amount subject to judicial determination.

Wuhan Huakang Century Jingjing Technology Co., Ltd. has been preliminarily selected as the winning bidder for the "First Phase Project of Taizhou Hospital Affiliated to Wenzhou Medical University (Purification Engineering)". The bid price is RMB 82,474,000. The company expects this project to positively impact its future performance.